title: FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.
abstract: Over recent years, [18F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography (FDG-PET/CT) has proven its role as a staging modality in patients with non-small cell lung cancer (NSCLC). The purpose of this review was to present the evidence to use FDG-PET/CT for response evaluation in patients with NSCLC, treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI). All published articles from 1 November 2003 to 1 November 2013 reporting on 18F-FDG-PET response evaluation during EGFR-TKI treatment in patients with NSCLC were collected. In total 7 studies, including data of 210 patients were eligible for analyses. Our report shows that FDG-PET/CT response during EGFR-TKI therapy has potential in targeted treatment for NSCLC. FDG-PET/CT response is associated with clinical and radiologic response and with survival. Furthermore FDG-PET/CT response monitoring can be performed as early as 1-2 wk after initiation of EGFR-TKI treatment. Patients with substantial decrease of metabolic activity during EGFR-TKI treatment will probably benefit from continued treatment. If metabolic response does not occur within the first weeks of EGFR-TKI treatment, patients may be spared (further) unnecessary toxicity of ineffective treatment. Refining FDG-PET response criteria may help the clinician to decide on continuation or discontinuation of targeted treatment.
authors: Matthijs H van Gool, Koen J Hartemink, Houke M Klomp, Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
authors: Matthijs H
authors: MH
authors: van Gool
authors: Matthijs H van Gool, Koen J Hartemink, Houke M Klomp, Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
authors: Tjeerd S
authors: TS
authors: Aukema
authors: Matthijs H van Gool, Koen J Hartemink, Houke M Klomp, Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
authors: Koen J
authors: KJ
authors: Hartemink
authors: Matthijs H van Gool, Koen J Hartemink, Houke M Klomp, Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
authors: Renato A
authors: RA
authors: Valdés Olmos
authors: Matthijs H van Gool, Koen J Hartemink, Houke M Klomp, Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
authors: Harm
authors: H
authors: van Tinteren
authors: Matthijs H van Gool, Koen J Hartemink, Houke M Klomp, Department of Surgical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
authors: Houke M
authors: HM
authors: Klomp
keywords: Computed tomography; Epidermal growth factor receptor-tyrosine kinase inhibitors therapy; Non-small cell lung cancer; Positron emission tomography-computed tomography; Response monitoring